CYTOMEGALOVIRUS ISOLATE RESISTANT TO GANCICLOVIR AND FOSCARNET FROM A MARROW TRANSPLANT PATIENT

被引：92
|
作者：
KNOX, KK
DROBYSKI, WR
CARRIGAN, DR
机构：
[1] MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226
[2] MED COLL WISCONSIN,BONE MARROW TRANSPLANT PROGRAM,MILWAUKEE,WI 53226
来源：
LANCET | 1991年 / 337卷 / 8752期
关键词：
D O I：
10.1016/0140-6736(91)92965-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1292 / 1293
页数：2
相关论文
共 50 条
  • [41] GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT
    GOODRICH, JM
    BOWDEN, RA
    FISHER, L
    KELLER, C
    SCHOCH, G
    MEYERS, JD
    ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) : 173 - 178
  • [42] EARLY TREATMENT OF CMV INFECTIONS IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS WITH FOSCARNET OR GANCICLOVIR
    BACIGALUPO, A
    VANLINT, MT
    TEDONE, E
    MORO, F
    SANNA, MA
    LONGREN, M
    TRESPI, G
    FRASSONI, F
    OCCHINI, D
    GUALANDI, F
    LAMPARELLI, T
    MARMONT, AM
    BONE MARROW TRANSPLANTATION, 1994, 13 (06) : 753 - 758
  • [43] Ganciclovir-Resistant Cytomegalovirus Infections among Lung Transplant Recipients Are Associated with Poor Outcomes despite Treatment with Foscarnet-Containing Regimens
    Minces, Lucio R.
    Hong Nguyen, M.
    Mitsani, Dimitra
    Shields, Ryan K.
    Kwak, Eun J.
    Silveira, Fernanda P.
    Abdel-Massih, Rima
    Pilewski, Joseph M.
    Crespo, Maria M.
    Bermudez, Christian
    Bhama, Jay K.
    Toyoda, Yoshiya
    Clancy, Cornelius J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 128 - 135
  • [44] The Use of Letermovir for Ganciclovir-Resistant Cytomegalovirus in Kidney Transplant Recipients
    Basic-Jukic, Nikolina
    Atic, Armin
    TURKISH JOURNAL OF NEPHROLOGY, 2022, 31 (03): : 257 - 260
  • [45] Use of Letermovir as Secondary Prophylaxis in Cardiac Transplant Patient, Mismatch for CMV (d plus /r-), Resistant to Ganciclovir and Foscarnet
    Sangani, A.
    Campanini, G.
    Puci, F.
    Truffelli, F.
    Lerta, S.
    Bruno, R.
    Seminari, E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S454 - S454
  • [46] Outcomes Associated with Ganciclovir-Resistant Cytomegalovirus in Lung Transplant Recipients
    Hammad, S.
    Shah, L.
    Restivo, M.
    Robbins, H.
    Scheffert, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S309 - S310
  • [47] SURVIVAL OF PATIENTS WITH AIDS AND CYTOMEGALOVIRUS DISEASE TREATED WITH GANCICLOVIR OR FOSCARNET
    HARB, GE
    BACCHETTI, P
    JACOBSON, MA
    AIDS, 1991, 5 (08) : 959 - 965
  • [48] FOSCARNET VERSUS GANCICLOVIR IN THE MANAGEMENT OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH AIDS
    MINOR, JR
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1991, 48 (11): : 2478 - 2479
  • [49] A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients
    Mattes, FM
    Hainsworth, EG
    Geretti, AM
    Nebbia, G
    Prentice, G
    Potter, M
    Burroughs, AK
    Sweny, P
    Walker, AFH
    Okwuadi, S
    Sabin, C
    Amooty, G
    Brown, VS
    Grace, SC
    Emery, VC
    Griffiths, PD
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (08): : 1355 - 1361
  • [50] Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis
    Walton, RC
    Whitcup, SM
    Mueller, BU
    Lewis, LL
    Pizzo, PA
    Nussenblatt, RB
    OPHTHALMOLOGY, 1995, 102 (12) : 1865 - 1870
12345